Floatz logo

Sars-Cov-2 Antigen-Specific Cytotoxic T-Lymphocytes

Malignant Solid Neoplasm

M.D. Anderson Cancer CenterCell therapyEarly Phase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

1412 Active assets in the Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Nabiximols
Jazz Pharmaceuticals
Phase 3BBB
Inno-206
M.D. Anderson Cancer Center
Phase 2BB
Vitamin B6
M.D. Anderson Cancer Center
Phase 4BB
PROPOFOL
Hong Kong Children's Hospital
Phase 4BB
Rivoceranib
Jiangsu HengRui Medicine Co., Ltd.
Phase 4BB

View all 50 →

Same molecule, other indications

Sars-Cov-2 Antigen-Specific Cytotoxic T-Lymphocytes is also rated in:

hematopoietic and lymphoid cell neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
COVID-19Dormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →